Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141531
Status:
COMPLETED
Last Update Posted:
2012-06-14
First Post:
2005-08-30
Brief Title:
Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
Sponsor:
Spectrum Pharmaceuticals Inc
Organization:
Spectrum Pharmaceuticals Inc
Organization Data
Organization:
Spectrum Pharmaceuticals Inc
Class:
INDUSTRY
Study ID:
SPI 05-003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Spectrum Pharmaceuticals Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None